This inventor holds 1 USPTO granted patent. Top assignee: Roche Diagnostics Gmbh. Active years: 2002.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2002
Title: Goosen Van Muijen: Innovator in Tumor Metastasis Research
Introduction
Goosen Van Muijen is a notable inventor based in Nijmegen, Netherlands. He has made significant contributions to the field of cancer research, particularly in understanding tumor progression and metastasis. His work has implications for improving diagnostic processes in oncology.
Latest Patents
Goosen Van Muijen holds a patent for a nucleic acid molecule that is upregulated in metastatic human tumor cells. This nucleic acid molecule, referred to as URIM, has the nucleic acid sequence SEQ ID NO:1 and is capable of inducing tumor progression and/or metastasis. Additionally, the URIM protein of SEQ ID NO:2 is provided in the patent. The patent also outlines a process for determining whether a tumor sample has metastatic potential. He has 1 patent to his name.
Career Highlights
Goosen Van Muijen is currently employed at Roche Diagnostics GmbH, where he continues to advance research in the field of diagnostics and cancer treatment. His work at Roche has allowed him to collaborate with leading experts in the field.
Collaborations
Some of his notable coworkers include Tobias Hildebrandt and Ulrich Weidle, who have also contributed to advancements in cancer research.
Conclusion
Goosen Van Muijen's innovative work in the field of tumor metastasis is paving the way for new diagnostic methods and treatments. His contributions are vital to the ongoing fight against cancer.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile